
Vanda Pharmaceuticals (VNDA) Stock Forecast & Price Target
Vanda Pharmaceuticals (VNDA) Analyst Ratings
Bulls say
Vanda Pharmaceuticals is well-positioned for long-term success with their anticipated market entry of Bysanti (milsaperidone) in the treatment of bipolar I disorder and schizophrenia, backed by clinical studies and a strong safety profile. With the potential for market exclusivity until 2044, Vanda can also leverage their established infrastructure to effectively launch and incentivize the switch from iloperidone. This added service revenue and high probability of approval make Vanda a strong buy, with a raised 12-month price target of $24 per share.
Bears say
Vanda Pharmaceuticals is facing several risks that could negatively impact its stock, including slower-than-expected sales, generic erosion, negative pricing developments, regulatory setbacks, negative clinical readouts, adverse developments on the M&A front, and potential dilution. These risks, combined with the company's current valuation and high dependence on its Fanapt product, contribute to a negative outlook on the stock. The company's current valuation, projected sales, and potential dilution risks indicate a price objective of $21 per share, but achieving that target is not guaranteed due to the aforementioned risks in the pharmaceutical industry.
This aggregate rating is based on analysts' research of Vanda Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Vanda Pharmaceuticals (VNDA) Analyst Forecast & Price Prediction
Start investing in Vanda Pharmaceuticals (VNDA)
Order type
Buy in
Order amount
Est. shares
0 shares